Study Group: Prescribers of Strattera for ADHD(?)
Council Members in this Study Group: 72
Request a survey with this Study Group
Leading Experts in this Study Group
Daniel Wynn, MD
Director, Clinical Research
Consultants In Neurology Ltd.
Daniel Wynn, MD, FACN, FAASM, is a Director of Clinical Research at Consultants in Neurology in Chicago, Illinois. He has expertise in a wide variety of neurological illnesses and has served as a principal investigator in over 100 clinical trials in multiple sclerosis, Alzheimer's disease, stroke, chronic...
Psychiatrist
North Scottsdale Psychiatric Specialists
Robert Schulte, MD, is a Private Practitioner and a Psychiatrist at North Scottsdale Psychiatric Specialists in Arizona. He is board certified in Adult Psychiatry and Child and Adolescent Psychiatry with extensive experience with children and adult's re-psychotherapy and psychopharmacology and the treatment...
President
Red Oak Psychiatry Associates, P. A.
Lawrence Ginsberg, MD, is President and CEO of Red Oak Psychiatry Associates, PA, a multidisciplinary mental health group in Houston, Texas. Dr. Ginsberg's research interests include psychopharmacology, addiction medicine, and forensic psychiatry. His areas of clinical expertise are attention deficit...
Louis Sanfilippo, MDPresident
LCS Group, LLC
Louis Sanfilippo, MD, is President of the LCS Group, since April 2008, a consulting firm focused on pharmaceutical development and market strategy. He is an Assistant Clinical Professor of Psychiatry at Yale School of Medicine and in private practice. Dr. Sanfilippo has served management and scientific...
Related Study Groups
| Study Group Name | Members |
|---|---|
| Physicians who Treat ADHD (US) | 382 |
| Adderall XR Prescribers (US) | 83 |
| Psychiatrists | 1442 |
| Psychiatrists (US) | 1105 |
| Physicians who Treat Depression (US) | 365 |
| SSRI Prescribers (US) | 243 |
| Physicians who Treat Schizophrenia (US) | 326 |
GLG NewsSMAnalyses by this Study Group's Leading Experts(?)
“Personalized medical diagnositics” looks to be evolving as a high impact area in neuropsychiatric drug development. Such ‘genetic biomarker’ platforms, based on either pharmacogenetic profiles coming from DNA blueprints or gene products from a simple blood draw, aim to identify patients who are...
‘One drug, many uses’ can make lots of sense clinically and commercially. Seeking additional FDA indications for a specific drug has obvious business benefits: greater revenue stream, improved branding, potentially longer market exclusivity, greater franchising potential of the drug...
Lundbeck has now disclosed the mechanism of action of its “mixed serotonin modulator and stimulator,” albeit buried in a first quarter report. Data on LuAA21004, Lundbeck’s lead antidepressant jointly in development with Takeda, was released at the Scandinavian College of Neuro-Psychopharmacology...
Extavia, Novartis' brand of interferon beta 1b, has been approved for the treatment of multiple sclerosis by the European Union. With FTY72, Fingolimod, Novartis has the eye on filing NDA by the end of 2009. While essentially identical to Bayer's Betaferon interferon beta 1b,...
The data on ABT-089 in adults has been released with positive results, whereas the adolescent/childhood trial is on-going for this novel compound for ADHD. The key difference is the potential to improve learning, not simply regain attention and lessen hyperactivity.
Most Common Company Types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Other Freestanding Healthcare Facility
- Non-Academic Community Hospital or Clinic
Most Common Job Types:
- Physician - Attending Physician
- Owner
- Physician - Director
- Physician - Division Head
- President
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms